drugset

drugset / Trial / NCT00281554

Study of RSD1235 to Evaluate Safety in Patients With Atrial Fibrillation

NCT00281554 ↗

Phase 3 Completed 254 enrolled Astellas Pharma Inc Advanz Pharma · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is designed to determine the safety of RSD1235 in patients with atrial fibrillation.

Timeline

Start: 2005-10
Primary completion: 2007-01
Completion: 2007-01

Publications

Stiell IG, Dickinson G, Butterfield NN, Clement CM, Perry JJ, Vaillancourt C, Calder LA. Vernakalant hydrochloride: A novel atrial-selective agent for the cardioversion of recent-onset atrial fibrillation in the emergency department. Acad Emerg Med. 2010 Nov;17(11):1175-82. doi: 10.1111/j.1553-2712.2010.00915.x.
Stiell IG, Roos JS, Kavanagh KM, Dickinson G. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm. Am Heart J. 2010 Jun;159(6):1095-101. doi: 10.1016/j.ahj.2010.02.035.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Vernakalant	Other / unclassified	3 mg/kg	—

Indications